These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 7799704

  • 1. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
    Howell A, DeFriend D, Robertson J, Blamey R, Walton P.
    Lancet; 1995 Jan 07; 345(8941):29-30. PubMed ID: 7799704
    [Abstract] [Full Text] [Related]

  • 2. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
    Howell A, Robertson J.
    Lancet; 1995 Apr 15; 345(8955):989-90. PubMed ID: 7772169
    [No Abstract] [Full Text] [Related]

  • 3. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
    Robertson JF.
    Br J Cancer; 2001 Nov 15; 85 Suppl 2(Suppl 2):11-4. PubMed ID: 11900210
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer.
    Dowsett M, Johnston SR, Iveson TJ, Smith IE.
    Lancet; 1995 Feb 25; 345(8948):525. PubMed ID: 7861903
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
    Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI.
    J Natl Cancer Inst; 1995 May 17; 87(10):746-50. PubMed ID: 7563152
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
    Howell A, Osborne CK, Morris C, Wakeling AE.
    Cancer; 2000 Aug 15; 89(4):817-25. PubMed ID: 10951345
    [Abstract] [Full Text] [Related]

  • 10. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.
    Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE, Dowsett M.
    Int J Cancer; 1997 Aug 07; 72(4):608-13. PubMed ID: 9259399
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic potential of pure antioestrogens in the treatment of breast cancer.
    Wakeling AE.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):771-5. PubMed ID: 2285589
    [Abstract] [Full Text] [Related]

  • 12. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
    Robertson JF.
    J Steroid Biochem Mol Biol; 2001 Dec 20; 79(1-5):209-12. PubMed ID: 11850227
    [Abstract] [Full Text] [Related]

  • 13. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A.
    J Clin Oncol; 2002 Aug 15; 20(16):3386-95. PubMed ID: 12177098
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Fulvestrant: a new agent in endocrine treatment for breast cancer].
    Juretić A, Sarić N, Bisof V, Basić-Koretić M.
    Lijec Vjesn; 2006 Aug 15; 128(1-2):31-6. PubMed ID: 16640225
    [Abstract] [Full Text] [Related]

  • 16. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K, Curran MP, Plosker GL.
    Drugs; 2004 Aug 15; 64(6):633-48. PubMed ID: 15018596
    [Abstract] [Full Text] [Related]

  • 17. Time to response: comparison of fulvestrant and oral endocrine agents.
    Dodwell D, Pippen J.
    Clin Breast Cancer; 2006 Aug 15; 7(3):244-7. PubMed ID: 16942641
    [Abstract] [Full Text] [Related]

  • 18. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer.
    Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM, Katzenellenbogen BS.
    Ann N Y Acad Sci; 1995 Jun 12; 761():148-63. PubMed ID: 7625718
    [No Abstract] [Full Text] [Related]

  • 19. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R.
    Breast Cancer Res Treat; 2007 Nov 12; 106(1):105-12. PubMed ID: 17295045
    [Abstract] [Full Text] [Related]

  • 20. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
    Franco S, Perez A, Tan-Chiu E, Frankel C, Vogel CL.
    Breast Cancer Res Treat; 2004 Nov 12; 88(2):103-8. PubMed ID: 15564793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.